What is CUSIP 745848101?

CUSIP 745848101 is the security identifier used in SEC filing datasets for LUNG - Pulmonx Corp - Common Stock.

Who owns LUNG - Pulmonx Corp - Common Stock based on 13F filings?

32 institutions reported positions in LUNG - Pulmonx Corp - Common Stock as of Q2 2026. Open the latest holders period and ownership history tables on this page for position-level details.

Security Snapshot

Pulmonx Corp - Common Stock (LUNG) Institutional Ownership

CUSIP: 745848101

13F Institutional Holders and Ownership History from Q4 2020 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

Shares (Excl. Options)

2,262,971

Price

$1.30

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Common Stock
Symbol: LUNG on Nasdaq
All holders as of 30 Jun 2026: Q2 2026
Total 13F shares: 2,262,971
Total 13F value: $2,947,443
Portfolio coverage rank: 0%
Share change: -3,090,645
Value change: -$4,011,155
Number of holders: 32
Shares outstanding: 42,540,056
SEC-reported price per share: $1.47
Insider filing price: $1.47

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Key facts

LUNG - Pulmonx Corp - Common Stock is tracked under CUSIP 745848101.
32 institutions reported positions in Q2 2026.
5 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder count moved from 111 to 32 between Q1 2026 and Q2 2026.
SEC-reported value moved from $40,902,506 to $2,947,443.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 32 institutions filings for Q2 2026.

Open SEC evidence

Security key

745848101

Latest holder period

Q2 2026

13F holders

13D/G owners

CIK / CUSIP context first

Open Q2 2026 holders LUNG full holder history Pulmonx Corp SEC filings Pulmonx Corp company facts Pulmonx Corp insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 745848101:

Q2 2026 (32 holders) Q1 2026 (111 holders) Q4 2025 (113 holders) Q3 2025 (104 holders) Q2 2025 (113 holders) Q1 2025 (114 holders) Q4 2024 (117 holders) Q3 2024 (112 holders) Q2 2024 (108 holders) Q1 2024 (117 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

LUNG

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
PRIMECAP MANAGEMENT CO/CA/	12%	-10%	$8,029,839	-$742,073	4,956,691	-8.5%	PRIMECAP MANAGEMENT CO/CA/	30 Sep 2025
MORGAN STANLEY	8.5%	+12%	$17,530,110	+$2,200,052	3,390,737	+14%	Morgan Stanley	31 Mar 2025
Soleus Capital Master Fund, L.P.	6.5%		$4,344,113		2,665,100		Soleus Capital Master Fund, L.P.	06 Mar 2026
BlackRock, Inc.	1.8%	-71%	$995,514	-$2,508,253	765,721	-72%	BlackRock, Inc.	30 Jun 2026
FMR LLC	0.2%	-104%	$114,736	-$3,416,852	70,825	-97%	FMR LLC	31 Oct 2025

As of 30 Jun 2026, 32 institutional investors reported holding 2,262,971 shares of Pulmonx Corp - Common Stock (LUNG). This represents 5.3% of the company’s total 42,540,056 outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Latest

Q2 2026

Rows shown

1-23 of 23

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2026 Q2	2,262,971	$2,947,443	-$4,011,155			$1.30	32
2026 Q1	31,742,669	$40,902,506	-$1,886,758	$138,804	$0	$1.29	111
2025 Q4	32,396,800	$71,586,474	+$3,228,827	$285,532	$123,097	$2.21	113
2025 Q3	31,835,122	$51,571,453	-$11,678,469		$34,155	$1.62	104
2025 Q2	36,256,022	$93,898,311	-$4,596,833	$0	$0	$2.59	113
2025 Q1	36,156,132	$243,324,576	+$1,663,003	$1,452,741	$17,498	$6.73	114
2024 Q4	35,870,967	$243,565,337	+$1,640,704	$1,445,949	$3,395	$6.79	117
2024 Q3	35,563,337	$293,811,542	+$7,857,689	$1,687,844	$2,487	$8.29	112
2024 Q2	34,744,517	$220,280,080	-$2,027,570	$0	$2,536	$6.34	108
2024 Q1	34,672,382	$321,430,455	+$7,599,744	$11,124	$11,124	$9.27	117
2023 Q4	33,520,168	$427,381,569	+$18,995,295	$38,250	$168,300	$12.75	122
2023 Q3	33,253,122	$343,505,198	-$6,689,600	$1,033	$363,616	$10.33	113
2023 Q2	33,869,172	$443,992,925	-$9,642,079	$15,732	$964,896	$13.11	112
2023 Q1	34,707,575	$388,032,205	+$25,513,692	$1,647,540	$4,143,144	$11.18	101
2022 Q4	33,773,100	$284,706,913	-$83,075,336	$592,629	$124,764	$8.43	111
2022 Q3	34,912,391	$581,637,070	-$4,909,166	$532,000	$210,000	$16.66	100
2022 Q2	35,341,147	$520,187,047	-$7,902,826	$0	$1,472,000	$14.72	102
2022 Q1	34,711,340	$861,059,885	+$56,937,629	$12,468,000	$4,667,000	$24.81	105
2021 Q4	32,045,807	$1,027,712,027	+$25,949,573	$3,333,000	$4,134,080	$32.07	108
2021 Q3	31,600,475	$1,136,986,158	+$204,291,164	$515,000	$3,363,680	$35.98	118
2021 Q2	25,771,799	$1,136,970,052	+$216,275,676		$6,150,000	$44.12	112
2021 Q1	20,788,776	$950,879,909	+$115,760,357		$1,880,000	$45.74	107
2020 Q4	17,288,638	$1,179,671,046	+$1,018,686,046			$69.02	98